FDA Allows U.S. Sales of Iclusig to Resume Under Strict Safety Surveillance

Drug Industry Daily
A A
The FDA will allow Ariad Pharmaceuticals to resume U.S. sales of its leukemia drug Iclusig, but the drugmaker must now implement a host of stringent safety measures designed to address the drug’s risk of blood clots.

To View This Article:

Login

Subscribe To Drug Industry Daily